Papillary Thyroid Cancer Clinical Trial
Official title:
Overdiagnosis of Thyroid Cancer in the Marne and Ardennes Departments of France From 1975 to 2014
Introduction - Incidence of thyroid cancer has increased considerably in France in recent
years, but the mortality rate has declined only slightly. Part of this increased incidence
could be attributable to overdiagnosis. We aimed to estimate the contribution of
overdiagnosis to the incidence of papillary thyroid cancer.
Material and methods. - Incidence rates were calculated based on data from the specialised
Marnes-Ardennes thyroid cancer registry, for cancers diagnosed between 1975 and 2014, by age
category and by five-year period. The population was divided into two groups according to
pTNM classification at diagnosis (i.e. localised or invasive). Overdiagnosis was defined as
the difference in incidence rates between the invasive cancer and localised cancer groups.
This rate was then divided by the incidence rate in the localised cancer group for the most
recent period (2010-2014) to obtain the proportion of cancers attributable to overdiagnosis.
Introduction - Incidence of thyroid cancer has increased considerably in France in recent
years, but the mortality rate has declined only slightly. Part of this increased incidence
could be attributable to overdiagnosis. We aimed to estimate the contribution of
overdiagnosis to the incidence of papillary thyroid cancer.
Material and methods. - We included all subjects living in the Marne or Ardennes Departments
of France and who were diagnosed with papillary thyroid cancer between 1975 and 2014. We
recorded socio-demographic variables, i.e. age at diagnosis and sex. Cancer characteristics
were also recorded, namely year of diagnosis, International Classification of Diseases (ICD)
10th revision code associated with the papillary cancer, and the pTNM 2002 status. Incidence
rates were calculated based on data from the specialised Marnes-Ardennes thyroid cancer
registry, for cancers diagnosed between 1975 and 2014, by age category and by five-year
period. The population was divided into two groups according to pTNM classification at
diagnosis (i.e. localised or invasive). Overdiagnosis was defined as the difference in
incidence rates between the invasive cancer and localised cancer groups. This rate was then
divided by the incidence rate in the localised cancer group for the most recent period
(2010-2014) to obtain the proportion of cancers attributable to overdiagnosis.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01441154 -
Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment
|
||
| Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT03469011 -
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
|
Phase 1 | |
| Recruiting |
NCT05752669 -
Oxidative Stress and Mitochondrial TERT in Papillary Thyroid Cancer.
|
||
| Recruiting |
NCT04076514 -
The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
|
||
| Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
| Active, not recruiting |
NCT01723202 -
Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer
|
Phase 2 | |
| Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02568267 -
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
|
Phase 2 | |
| Unknown status |
NCT02140476 -
Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy
|
N/A | |
| Recruiting |
NCT06286631 -
Prediction of Lymph Node Metastasis in Patients With Thyroid Malignancy by a New Scale
|
||
| Completed |
NCT06325787 -
Image-guided Thermal Ablation vs. Lobectomy for Solitary Papillary Thyroid Microcarcinoma
|
N/A | |
| Terminated |
NCT01974284 -
Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma
|
N/A | |
| Active, not recruiting |
NCT00984191 -
Pilot 99mTechnetium-MIBI Single Photon Emission Computed Tomography - Computed Tomography (SPECT-CT) in Papillary Carcinoma (CA) Thyroid
|
N/A | |
| Active, not recruiting |
NCT04731467 -
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
| Completed |
NCT02178345 -
Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
|
||
| Not yet recruiting |
NCT06133374 -
Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples
|
||
| Completed |
NCT03470259 -
Precision Thyroid Cancer Surgery With Molecular Fluorescent Guided Imaging
|
Phase 1 | |
| Active, not recruiting |
NCT04129411 -
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
|
N/A |